Cite
Feasibility and Safety of Systemic rAAV9-hNAGLU Delivery for Treating MPS IIIB: Toxicology, Bio-distribution and Immunological Assessments in Primates
MLA
Aaron S. Meadows, et al. “Feasibility and Safety of Systemic RAAV9-HNAGLU Delivery for Treating MPS IIIB: Toxicology, Bio-Distribution and Immunological Assessments in Primates.” Human Gene Therapy Clinical Development, Mar. 2014, p. 150127063140004. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........29a94ce2ea2b9afc16d328b878908716&authtype=sso&custid=ns315887.
APA
Aaron S. Meadows, Darren A. Murrey, Kevin M. Flanigan, Laurie Goodchild, Douglas M. McCarty, Tierra Ware, Christopher M. Walker, Haiyan Fu, Brad Bolon, William G. Bremer, La Perle K, Katie Campbell, Bartholomew J. Naughton, Duncan Fj, & Kim L. McBride. (2014). Feasibility and Safety of Systemic rAAV9-hNAGLU Delivery for Treating MPS IIIB: Toxicology, Bio-distribution and Immunological Assessments in Primates. Human Gene Therapy Clinical Development, 150127063140004.
Chicago
Aaron S. Meadows, Darren A. Murrey, Kevin M. Flanigan, Laurie Goodchild, Douglas M. McCarty, Tierra Ware, Christopher M. Walker, et al. 2014. “Feasibility and Safety of Systemic RAAV9-HNAGLU Delivery for Treating MPS IIIB: Toxicology, Bio-Distribution and Immunological Assessments in Primates.” Human Gene Therapy Clinical Development, March, 150127063140004. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........29a94ce2ea2b9afc16d328b878908716&authtype=sso&custid=ns315887.